| Management of rosiglitazone-induced edema: two case reports and a review of the literature. | |
| | |
MedLine Citation:
|
PMID: 12396745 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The thiazolidinediones are an important class of insulin-sensitizing agents used for the treatment of type 2 diabetes. Similar to other antidiabetic agents, use of the thiazolidinediones is limited by adverse drug reactions. Specifically, use of the thiazolidinediones is associated with a triad of fluid retention, edema, and weight gain. In premarketing clinical trials, edema was reported to occur infrequently with minimal severity. However, several published cases from postmarketing data demonstrate that thiazolidinedione-induced fluid retention, exhibited by the initial onset of peripheral edema and weight gain, can progress to a more severe form of pulmonary edema that is refractory to diuretic therapy with resolution of symptoms only through discontinuation of the offending thiazolidinedione. In clinical practice, the occurrence of edema secondary to a thiazolidinedione drug may occur more frequently than reported. Two cases presented in this report illustrate a different outpatient management approach that enables both desired glycemic control and minimal fluid retention while using the thiazolidinediones. |
| | |
Authors:
|
Fei Wang; Lauren M Aleksunes; Louise A Reagan; Cunegundo M Vergara |
Related Documents
:
|
11987745 - G-induced vestibular dysfunction ('the wobblies') among aerobatic pilots: a case report... 2375555 - Labetalol hepatotoxicity. 15563365 - Serotonin reuptake inhibitor induced sensory disturbances. 7485105 - Heparin-induced thrombocytopenia and fatal thrombosis in a patient with activated prote... 956265 - Ataxia-telangiectasia. 9646315 - Lupus pernio with involvement of nasal cavity and maxillary sinus. |
Publication Detail:
|
Type: Case Reports; Journal Article; Review |
Journal Detail:
|
Title: Diabetes technology & therapeutics Volume: 4 ISSN: 1520-9156 ISO Abbreviation: Diabetes Technol. Ther. Publication Date: 2002 |
Date Detail:
|
Created Date: 2002-10-24 Completed Date: 2003-04-21 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 100889084 Medline TA: Diabetes Technol Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 505-14 Citation Subset: IM |
Affiliation:
|
Department of Pharmacy Practice, School of Pharmacy, University of Connecticut, Storrs, Connecticut 06269-2092, USA. fwang@harthosp.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Body Weight Clinical Trials as Topic Diabetes Mellitus / drug therapy* Diabetes Mellitus, Type 2 / drug therapy* Diuresis / drug effects* Edema / chemically induced*, therapy Female Hemoglobin A, Glycosylated / metabolism Humans Hypoglycemic Agents / adverse effects* Middle Aged Obesity* Thiazoles / adverse effects* Thiazolidinediones* |
| Chemical | |
Reg. No./Substance:
|
0/Hemoglobin A, Glycosylated; 0/Hypoglycemic Agents; 0/Thiazoles; 0/Thiazolidinediones; 122320-73-4/rosiglitazone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Ultrasound-assisted insulin delivery and noninvasive glucose sensing.
Next Document: From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example.